Credit: Gorodenkoff/Shutterstock
Despite the buzz around artificial intelligence (AI), most industry insiders know that the use of machine learning (ML) in drug discovery is nothing new. For more than a decade, researchers have used computational techniques for many purposes, such as finding hits, modelling drug-protein interactions, and predicting reaction rates.
Optibrium, a developer of software and artificial intelligence (AI) solutions for drug discovery, has announced the opening of its US subsidiary, Optibrium Inc. Dr Tamsin Mansley has been promoted to president of the new subsidiary to lead its US-based team and business operations. The opening aims to strengthen the Company’s direct sales, and technical and application support for new and existing US customers, expanding the global presence and customer base of Optibrium’s StarDrop and Augmented Chemistry platforms.
Selectivity is a crucial property in the development of new active pharmaceutical ingredients (APIs). Binding site comparisons within a protein family are key to understanding how to modulate the selectivity profile of a potential new API, which includes understanding both on- and off-target effects.
Credit: Gorodenkoff/Shutterstock
Benchling has introduced capabilities for designing, modelling, and studying natural and chemically modified RNA in a single solution
Atos has unveiled its new exascale-class supercomputer, the BullSequana XH3000, a hybrid computing platform that will enable scientists and researchers to advance research in sectors such as weather forecasting and climate change, new drug discovery, genomics
EMBL-EBI training course. Credit: Jeff Dowling
Sophia Ktori explores the role cheminformatics software providers play in supporting scientists in academia and industry to better understand the properties of potential new drugs.
Robert Roe explores the services and software available to support organisations drug discovery research
Sophia Ktori considers how software integration helps ensure scientists work efficiently in the laboratory
Synthace and Ipsen two European specialists in biopharma and integrative software are working together to advance drug discovery by reducing the cost of design, construction and screening of new compounds
Optibrium, Intellegens and Medicines Discovery Catapult have announced that they have been awarded a £1 million grant from Innovate UK to support the development of artificical Intelligence (AI) in drug discovery
Credit: Gorodenkoff/Shutterstock
Laboratory informatics tools have continued to converge around requirements for data management and movement within an organisation.
Credit: Larichshutterstock/Shutterstock
A round-up of the latest technologies available to scientists and researchers using HPC
Credit: Carlos Castilla/Shutterstock
A round-up of the latest processing and memory technologies
